On May 14, 2018, Eli Lilly announced an agreement to acquire AurKa Pharma, a company established by TVM Capital Life Science to develop an oncology compound, in a deal worth up to $575 million. AurKa Pharma is developing AK-01, an Aurora kinase A inhibitor that was originally discovered by LillyOriginal Article
You may also like
New alloys for manufacturing freeze-dryers
Navigating the Complexities of Emerging Therapy...
INTERPHEX 2025: Preventing Spills in the Manufacturing...
Agentic AI Growth Predicted, but More Than Half of...
Microsoft and SkyCell Collaborate on Pharma Supply...
Siemens Acquires Dotmatics, Extending AI Software...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.